Zymeworks is pleased to announce, along with our partners Jazz Pharmaceuticals and BeiGene, new and updated data from two ongoing clinical trials evaluating zanidatamab, a HER2-targeted bispecific antibody for the treatment of solid tumors, at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2 to June 6 in Chicago, IL.

Results from the pivotal phase 2b HERIZON-BTC-01 study of zanidatamab in previously treated HER2-amplified biliary tract cancer (abstract #4008) will be presented by Dr. Shubham Pant in an oral presentation on Friday, June 2, during the Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary Session from 2:45-5:45 pm Central Daylight Time (CDT).

Updated clinical data from a phase 1b/2 study evaluating zanidatamab in combination with docetaxel as first-line therapy for patients with advanced HER2-positive breast cancer (abstract #1044) will be presented in the Breast Cancer-Metastatic poster session on Sunday, June 4 from 8:00-11:00 am CDT.

The presentations will be available to conference registrants on the conference website as well as to the general public at www.zymeworks.com/publications at the time of presentation at the conference.